Tarsus Pharmaceuticals (TARS) Net Cash Flow (2019 - 2026)

Tarsus Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$82.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 201.29% year-over-year to -$82.0 million; the TTM figure through Mar 2026 stood at -$74.2 million (down 382.95% YoY), while the FY2025 annual figure was $88.8 million, up 169.63% from the prior year.
• Net Cash Flow was -$82.0 million for Q1 2026 at Tarsus Pharmaceuticals, down from $70.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $119.9 million in Q3 2023 to a low of -$97.8 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$3.9 million across 5 years, with a median of -$4.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 4469.8% in 2024, then soared 429.09% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$97.8 million in 2022, then jumped by 98.24% to -$1.7 million in 2023, then slumped by 4469.8% to -$78.8 million in 2024, then surged by 189.96% to $70.9 million in 2025, then sank by 215.64% to -$82.0 million in 2026.
• The last three Net Cash Flow figures came in at -$82.0 million (Q1 2026), $70.9 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.